Abstract
Anaphylaxis to CoronaVac, an inactivated vaccine against COVID-19, is extremely rare. We report 12 cases of anaphylaxis after CoronaVac administration, focusing on clinical characteristics and management outcomes. Skin test and graded vaccine challenge were successfully performed in our cases and might be considered if an inactivated vaccine is the only remaining option.
Ethical Approval
This study was approved by the institutional review boards and ethics committees of the faculties of medicine for Siriraj Hospital and Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (approval no. 2021/477, 597/2564). All patients provided informed consent to participate and for the data to be published. This study was conducted in accordance with the Declaration of Helsinki.
Consent for Publication
All patients provided informed consent to participate and for the data to be published. The patients were informed that de-identified data would be used in scientific research and publications.
Acknowledgments
We would like to thank Dr. Anthony Tan for editing the English language. We also thank Dr. Jarungjit Kraiwattanapong for the endoscopic examination photographs.
Author Contributions
All authors have made substantial contributions to the conception and design of the research, the acquisition, analysis or interpretation of the data, and the drafting or revising of the manuscript. All authors have agreed to submit the manuscript to the current journal, have given their final approval of the version to be published, and have agreed to be accountable for all aspects of the work.
Disclosure
All authors declare no personal or professional conflicts of interest in this work.